A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Public ClinicalTrials.gov record NCT04569032. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.
Study identification
- NCT ID
- NCT04569032
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 82 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2020 (Actual)
- Primary completion
- May 9, 2024 (Actual)
- Completion
- Jan 12, 2026 (Actual)
- Last update posted
- Aug 13, 2026
2020 – 2026
United States locations
- U.S. sites
- 43
- U.S. states
- 8
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| Stanford Cancer Center | Stanford | California | 94305 | — |
| Stanford Hospital and Clinics, Investigational Drug Services | Stanford | California | 94305 | — |
| Rocky Mountain Cancer centers, LLP | Aurora | Colorado | 80012 | — |
| Rocky Mountain Cancer centers, LLP | Boulder | Colorado | 80303 | — |
| Rocky Mountain Cancer centers, LLP | Colorado Springs | Colorado | 80907 | — |
| Rocky Mountain Cancer centers, LLP | Denver | Colorado | 80218 | — |
| Rocky Mountain Cancer centers, LLP | Denver | Colorado | 80220 | — |
| Rocky Mountain Cancer centers, LLP | Lakewood | Colorado | 80228 | — |
| Rocky Mountain Cancer centers, LLP | Littleton | Colorado | 80120 | — |
| Rocky Mountain Cancer centers, LLP | Lone Tree | Colorado | 80124 | — |
| Rocky Mountain Cancer centers, LLP | Longmont | Colorado | 80504 | — |
| Rocky Mountain Cancer centers, LLP | Pueblo | Colorado | 81003 | — |
| Rocky Mountain Cancer centers, LLP | Thornton | Colorado | 80260 | — |
| Tulane Cancer Center | New Orleans | Louisiana | 70112 | — |
| Tulane Medical Center | New Orleans | Louisiana | 70112 | — |
| Memorial Sloan Kettering Cancer Center David H. Koch Center for Cancer Care | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Cleveland Clinic taussig Cancer Center Investigational Pharmacy | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic, The | Cleveland | Ohio | 44195 | — |
| Texas Oncology - Central/South Texas | Austin | Texas | 78705 | — |
| Texas Oncology - Central South (Balcones Dr) | Austin | Texas | 78731 | — |
| Texas Oncology - Central South (James Casey) | Austin | Texas | 78745 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| US Oncology Investigational Products Center (IPC) | Irving | Texas | 75063 | — |
| US Oncology Investigational Products Center(IPC) | Irving | Texas | 75063 | — |
| US Oncology lnvestigational Products Center (IPC) | Irving | Texas | 75063 | — |
| Texas Oncology-Northeast Texas | Longview | Texas | 75601 | — |
| Texas Oncology-Northeast Texas | Palestine | Texas | 75801 | — |
| Texas Oncology-Northeast Texas | Paris | Texas | 75460 | — |
| Texas Oncology-Northeast Texas | Tyler | Texas | 75702 | — |
| Virginia Oncology Associates | Chesapeake | Virginia | 23320 | — |
| Virginia Oncology Associates | Hampton | Virginia | 23666 | — |
| Virginia Oncology Associates | Newport News | Virginia | 23606 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| VCU Massey Cancer Center-Radiation Oncology | Richmond | Virginia | 23219 | — |
| VCU Medical Center -InPatient | Richmond | Virginia | 23219 | — |
| VCU Medical Center Critical Care Hospital | Richmond | Virginia | 23219 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23219 | — |
| VCU at Stony Point | Richmond | Virginia | 23235 | — |
| Massey Cancer Center Clinical & Translational Research Lab | Richmond | Virginia | 23298 | — |
| Virginia Oncology Associates | Virginia Beach | Virginia | 23456 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04569032, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04569032 live on ClinicalTrials.gov.